Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
59.22
+1.21 (2.09%)
Jul 25, 2025, 4:00 PM - Market closed

Company Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.

The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide.

It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050.

In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations.

It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc.
Praxis Precision Medicines logo
CountryUnited States
Founded2015
IPO DateOct 16, 2020
IndustryBiotechnology
SectorHealthcare
Employees116
CEOMarcio De'Souza

Contact Details

Address:
99 High Street, 30th Floor
Boston, Massachusetts 02110
United States
Phone617 300 8460
Websitepraxismedicines.com

Stock Details

Ticker SymbolPRAX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$19.00
CIK Code0001689548
CUSIP Number74006W108
ISIN NumberUS74006W2070
SIC Code2834

Key Executives

NamePosition
Marcio Silva De'Souza M.B.A.President, Chief Executive Officer and Director
Timothy Edwin KellyChief Financial Officer and Treasurer
Alex Nemiroff J.D.General Counsel and Secretary
Dr. Steven Petrou B.Sc. (Hons.), Ph.D.Co-Founder and Chief Scientific Officer
Lauren MastrocolaVice President of Finance and Principal Accounting Officer
Dr. Karl Hansen Ph.D.Chief Technical Operations Officer
Alex KaneVice President of Investor Relations and Corporate Communications
Kelly McCueChief People Officer
Alyssa J. S. WyantChief Regulatory and Quality Officer
Megan T. SniecinskiChief Business Officer

Latest SEC Filings

DateTypeTitle
Jul 22, 2025SCHEDULE 13GFiling
Jul 17, 20258-KCurrent Report
Jun 27, 20258-KCurrent Report
Jun 6, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 14, 2025SCHEDULE 13GFiling
May 13, 2025SCHEDULE 13G/AFiling